Index: Oncology Nutrition for Clinical Practice

A
Abraxane® (paclitaxel protein-bound) 112
acupuncture, traditional Chinese medicine, and cancer 58
ado-trastuzumab emtansine (Kadcyla®) 113
Adriamycin® (doxorubicin) 111,174,182,223
Adrucil® (fluorouracil, 5-FU) 110,174,182,189,202,223,268
Afinitor® (everolimus) 268
AICR/WCRF: personal recommendations for cancer prevention 17,54,61,249
alcohol 17-18,19,92,178,201,232,249,268-269
Aldesleukin® (interleukin-2 or IL-2) 102
Alimta® (pemetrexed) 214,269
alkaline diet 63
Alkeran® (melphalan) 110,214,268
aloe vera 69-70
alternative diets for cancer prevention 62-65
altretamine (Hexalen®) 214
American Cancer Society Guidelines 54,61,249
American Cancer Society Survivorship Guidelines 249
American Joint Committee on cancer tumor grading 10
anal cancer 196-197
anastrozole (Arimidex®) 103,174
androgen deprivation therapy (ADT) and prostate cancer 230
animal food/products 17,249
Index: Oncology Nutrition for Clinical Practice

angiogenesis inhibitors 100-101
anorexia 13, 89, 115
anticancer nutrition/diets 54, 63-65
anti-dumping diet 183, 221, 257-260
antioxidants 10, 70-71
anti-thymocyte globulin (Thymoglobulin®) 160
appendices
1: public health guidelines for cancer prevention/survivorship 249-250
2: assessing performance status 251
3: diet and nutrition guidelines after intestinal surgery 253-255
4: anti-dumping diet 257-260
5: diet and nutrition guidelines after ileostomy placement 261-263
6: MCT margarine and MCT vinaigrette dressing 265
7: overview of ketogenic diet 266
8: drug, nutrient, food, dietary supplement interactions with cancer medications 267-270
9: bowel regimen 271
Aromasin® (exemestane) 103, 175, 268
artificial hydration and nutrition in palliative/hospice care 243-244
ARA-C, cytarabine (Cytosar-U®) 110
Arimidex® (anastrozole) 103, 174
Association of Community Cancer Center Guidelines 48-49
Astagraf XL®, Prograf® (tacrolimus) 160
Avastin® (bevacizumab) 101, 167, 175, 182, 189
axitinib (Inlyta®) 267
ayurveda 53
azacitidine (Vidaza®) 110
Index: Oncology Nutrition for Clinical Practice

Azasan®, Imuran® (azathioprine) 160
azathioprine (Imuran®, Azasan®) 160

B
BCNU® (carmustine) 109
beclomethasone dipropionate (Beconase AQ®, Qvar®) 160
Beconase AQ®, Qvar® (beclomethasone dipropionate) 160
bendamustine (Treanda®) 109
beta carotene 67,71
beta glucans 67
bexarotene (Targretin®) 267
bevacizumab (Avastin®) 101,167,175,182,189
bicalutamide (Casodex®) 103
billing and reimbursement of oncology nutrition services 49-50
bioactive food components & carcinogenesis 12,79-80
biotherapy
- angiogenesis inhibitors 100-101
- cancer vaccine therapies 100
- categories of biotherapy agents 99
- cytokines 100,102
- monoclonal antibodies 99-100,113
- principles of biotherapy 99
- protein-targeted therapies 100-101
black cohosh 75
Blenoxane® (bleomycin) 111,202
bleomycin (Blenoxane®) 111,202
body fatness 13,15,17
### Index: Oncology Nutrition for Clinical Practice

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>body weight</td>
<td>249</td>
</tr>
<tr>
<td>bone and muscle health (and cancer survivorship)</td>
<td>13,88-89,93,161</td>
</tr>
<tr>
<td>bortezomib (Velcade®)</td>
<td>267</td>
</tr>
<tr>
<td>bowel obstruction/malignant bowel obstruction</td>
<td>88,216</td>
</tr>
<tr>
<td>bowel regimen</td>
<td>271</td>
</tr>
<tr>
<td>brachytherapy</td>
<td></td>
</tr>
<tr>
<td>- general review</td>
<td>104</td>
</tr>
<tr>
<td>- general types of brachytherapy placement</td>
<td>106</td>
</tr>
<tr>
<td>- possible acute &amp; late-occurring side effects of brachytherapy</td>
<td>107</td>
</tr>
<tr>
<td>- type and source duration of brachytherapy</td>
<td>106</td>
</tr>
<tr>
<td>brain cancer/tumors</td>
<td></td>
</tr>
<tr>
<td>- chapter (medical nutrition therapy for brain cancer)</td>
<td>165-169</td>
</tr>
<tr>
<td>- abnormal swallowing</td>
<td>167</td>
</tr>
<tr>
<td>- adverse effects of medications</td>
<td>167</td>
</tr>
<tr>
<td>- calorie restriction</td>
<td>168</td>
</tr>
<tr>
<td>- characteristics/treatments</td>
<td>165-166</td>
</tr>
<tr>
<td>- corticosteroid treatment</td>
<td>167</td>
</tr>
<tr>
<td>- end-of-life care</td>
<td>168</td>
</tr>
<tr>
<td>- goals for nutritional care</td>
<td>167</td>
</tr>
<tr>
<td>- ketogenic diet</td>
<td>168</td>
</tr>
<tr>
<td>- nutrition risk screening &amp; assessment</td>
<td>166</td>
</tr>
<tr>
<td>breads, grains &amp; cereals</td>
<td>249,258,262</td>
</tr>
<tr>
<td>breast cancer</td>
<td></td>
</tr>
<tr>
<td>- chapter (medical nutrition therapy for breast cancer)</td>
<td>171-180</td>
</tr>
<tr>
<td>- diet (composition, fatty acids, fiber, soyfood, green tea)</td>
<td>176-178</td>
</tr>
<tr>
<td>- hormone receptive cancers</td>
<td>172</td>
</tr>
<tr>
<td>- lymphedema</td>
<td>175</td>
</tr>
<tr>
<td>- medical nutrition therapy</td>
<td>176</td>
</tr>
<tr>
<td>- medical treatments</td>
<td>172-173</td>
</tr>
<tr>
<td>- nutrition impact symptoms of common treatment agents</td>
<td>173-175</td>
</tr>
<tr>
<td>- nutritional needs</td>
<td>176</td>
</tr>
<tr>
<td>- nutritional status</td>
<td>175-176</td>
</tr>
<tr>
<td>- risk factors</td>
<td>171</td>
</tr>
<tr>
<td>- staging</td>
<td>172</td>
</tr>
<tr>
<td>- tips to reduce breast cancer risk and progression</td>
<td>178</td>
</tr>
<tr>
<td>breastfeeding</td>
<td>17,19</td>
</tr>
</tbody>
</table>
Index: Oncology Nutrition for Clinical Practice

budesonide (Entocort EC®, Uceris® for oral; others for inhaled form) 160

Budwig Diet 63

busulfan (Myleran®) 109,267

C

cachexia 28,144

calcium 70-71,193,230-232

calorie restriction 43,168

Camptosar® (irinotecan) 167,182,189,214,223

cancer and nutrition
- chapter 9-14
- carcinogenesis and bioactive food components 12
- bioactive food components influence carcinogenesis 12
- medical treatments 11-12
- potential nutrition-related issues & outcomes across the cancer continuum 13
- screening 9
- staging 9-10
- statistics 9

cancer drugs:
All cancer drugs addressed in Oncology Nutrition for Clinical Practice are listed individually in this index. Both the generic name and common brand names are listed for each drug. However, some drugs have multiple brand names, and in these cases not all brand names are included. In addition, all drugs addressed in chapter 11, “nutritional effects of cancer treatment: chemotherapy, biotherapy, hormone therapy and radiation therapy” and appendix 8, “drug/nutrient/food/dietary supplement interactions with cancer medications” are listed under each title.

Oncology Nutrition for Clinical Practice also includes several tables addressing cancer medications/drugs used for various diagnoses. These are found on the following pages:
- breast cancer 173-175
- brain tumors 167
- esophageal cancer 182
- graft versus host disease 160
- GI cancers 189
- head and neck cancers 202
- ovarian cancer 214
# Index: Oncology Nutrition for Clinical Practice

- **pancreatic and bile duct cancer** 223

## Cancer prevention
- **chapter** 15-24
- AICR/WCRF personal recommendations and cancer prevention 17
- alcoholic drinks and cancer prevention 18-19
- body fatness/abdominal fatness and cancer prevention 15-16
- breastfeeding and cancer prevention 19
- dietary supplements and cancer prevention 19
- emerging topics and cancer prevention (e.g., soy, omega-3 fatty acids) 20-21
- foods processed with salt/sodium and cancer prevention 19
- physical activity and cancer prevention 16
- plant-based diet and cancer prevention 16-18
- public health guidelines for cancer prevention & survivorship 249
- red and processed meats and cancer prevention 18
(also see information under “nutrition and cancer prevention”)

## Cancer staging
- summary of TNM staging classification system 10

## Cancer survivorship
- **chapter** 87-96
- AICR/WCRF personal recommendations including those for cancer survivors 17
- biology of weight change in survivors 91
- diet and lifestyle recommendations for colorectal cancer survivors 193
- diet and nutrition recommendations for cancer prevention/survivorship 82
- dietary guidance & survivorship 92-93
- dietary intervention studies in cancer survivors 91-92
- dietary intervention for bone and muscle health 93
- dietary supplementation for survivors 93-94
- prostate cancer survivorship 232
- resources for cancer survivors 90
- public health guidelines for cancer prevention & survivorship 249
- select randomized clinical trials on nutrition & survivorship 92
- survivorship for ovarian cancer 216

## Cancer treatments
- angiogenesis inhibitors 101
- biotherapy 99
- brachytherapy 106
- chemotherapy 98,109-112
- cytokines 102
- general review 11-12
- goals of cancer therapy 98
- hormone therapy/hormonal agents 101,103
# Index: Oncology Nutrition for Clinical Practice

- monoclonal antibodies 113
- radiation therapy 102
- radiation therapy and breast cancer 172-173
- radiation therapy and head and neck cancer 202

dcapecitabine (Xeloda®) 110,173,182,189,214,223,267
carbamazepine (Tegretol®) 167
carboplatin (Paraplatin®) 109,182,189,202
carcinogenesis 10,12,79
carmustine (BCNU®) 109
casodex® (bicalutamide) 103
CCNSB®, CeeNU®, Gleostine® (lomustine systemic) 167
CeeNU®, CCNSB®, Gleostine® (lomustine systemic) 167
Celcept® (mycophenolate mofetil) 160
Certified Specialist in Oncology Nutrition (CSO) 49
cetuximab (Erbitux®) 113,182,189,202,267
chemotherapy 11,98-99,109-112
- classification, mechanism of action, administration, side effects 109-112
chlorambucil (Leukeran®) 109,267
CIPN and glutamine 211
(CIPN = chemotherapy induced peripheral neuropathy)
cisplatin (Platinol®) 109,182,189,202,214,223,267
coenzyme Q10 70,75
colorectal cancer 88,191-193
constipation 116
corticosteroids 160,167
Index: Oncology Nutrition for Clinical Practice

Cosmegen® (dactinomycin) 111

curcumin 57,70,75

cyclophosphamide (Cytoxan®, CTX) 109,173,214,267

cyclosporine (Sandimmune®) 160

cytarabine, ARA-C (Cytosar-U®) 110

cytokines
- examples of cytokines 102
- general definition 100
- possible side effects and nutritional implications of cytokines 102

Cytosar-U® (ARA-C, cytarabine) 110

Cytoxan® (CTX, cyclophosphamide) 109,173,214,267

**D**
dacarbazine (DTIC-dome®) 109
dactinomycin (Cosmegen®) 111
dairy foods (r/t calcium) 230-232,262,268
dasatinib (Sprycel®) 267
daunomycin® (daunorubicin) 111
daunorubicin (Daunomycin®) 111

Decadron® (dexamethasone) 167
deferasirox (Exjade®) 267

defining and developing an oncology nutrition program in a cancer center
- chapter 47-51
- billing and reimbursement 49-50
- defining and oncology nutrition program 47
- components of an oncology nutrition program 47-48
- measuring outcomes of nutrition care 51
- organizational structures for clinical nutrition services 49
- specifics of nutrition programming 50-51
Index: Oncology Nutrition for Clinical Practice

- staffing an oncology nutrition program 48
- standards of practice in oncology nutrition care 49
- standards of professional performance for oncology RDs 49

denosumab (Xgeva®, Prolia®) 113

Depakote® (divalproex sodium) 167
dexamethasone (Decadron®) 167
diabetes 221,224
diarrhea 88,116,260
diet history and nutrition risk screening 27
diet (and cancer/cancer symptom reduction / prevention / survivorship)
  - anti-dumping diet 183,190,257-259
  - breast cancer risk reduction 178
  - cancer prevention and survivorship 17,82,91-94,249
  - graft versus host disease 161
  - ileostomy placement 261-263
  - immunosuppressed patients 159
  - intestinal surgery 253
  - lifestyle recommendations- colorectal cancer 193
  - post-symptom, post-treatment diet therapy (for survivorship) 90
  - prostate cancer survivorship 232

diets for cancer prevention/treatment/survival 61-68
  - categories of functional foods 66
  - diets and functional foods for prevention/treatment/survival 62-68
  - functional food sources of select cancer-fighting compounds 67
  - integrative use of diets in cancer treatment/survival 62-65
  - integrative use of functional foods in cancer treatment/survival 66-67
  - omega-3 fatty acids 72
  - role of functional foods in the health care continuum 61

dietary fat and cancer prevention/survivorship 249
dietary supplements
  - and cancer survivors 68-78
  - antioxidant supplements and cancer 70-71
  - general discussion 55-56
  - interactions between cancer treatments & dietary supplements 69-70
  - RCTs on antioxidant supplementation and cancer risk 71
Index: Oncology Nutrition for Clinical Practice

- RCTs on vit D/calcium supplements and colon, breast, & prostate cancer 71
- resources on dietary supplements 72
- safety profile of dietary supplements 69
- vitamin D, calcium and cancer 70-71

Dilantin® (phenytoin) 167

divalproex sodium (Depakote®) 167
docetaxel (Taxotere®) 112,173,182,189,202,223
Doxil® (doxorubicin liposomal) 111,189,214
doxorubicin (Adriamycin®) 111,174,182,223
doxorubicin liposomal (Doxil®) 111,189,214

drug/nutrient/food/dietary supplement interactions with cancer medications:
(® = brand name)

axitinib (Inlyta®) 267
bexarotene (Targretin®) 267
bortezomib (Velcade®) 267
busulfan (Myleran®) 267
capcitabine (Xeloda®) 267
cetuximab (Erbitux®) 267
chlorambucil (Leukeran®) 267
cisplatin (Platinol®) 267
cyclophosphamide (Cytoxan®) 267
dasatinib (Sprycel®) 267
deferasirox (Exjade®) 267
erlotinib (Tarceva®) 267
everolimus (Afinitor®) 268
exemestane (Aromasin®) 268
fluorouracil (5-FU or Adrucil®) 268
gefitinib (Iressa®) 268
imatinib mesylate (Gleevec®) 268
lapatinib (Tykerb®) 268
melphalan (Alkeran®) 268
mercaptopurine (6-MP or Purinethol®) 268
methotrexate (Folex® or Rheumatrex®) 11,268
nilotinib (Tasigna®) 268
oxaliplatin (Eloxatin®) 268
panitumumab (Vectibix®) 269
pemetrexed (Alimta®) 269
procarbazine hydrochloride (Matulane®) 269
regorafenib (Stivarga®) 269

Note/clarification of information in the first printing of this book: high fat meals can alter the absorption of regorafenib/stivarga®. One study (with 24 healthy men) found that this medicine was better absorbed when taken with a meal providing 8.2 grams of fat and 319 calories as compared with a meal providing 54.6 grams of fat and 945 calories. As a result, most physicians ask patients to take this drug in the morning with a low fat meal providing < 8 grams of fat.

sipuleucel-T (Provenge®) 269
sorafenib (Nexavar®) 269
streptozocin (Zanosar®) 269
sunitinib (Sutent®) 269
tamoxifen (Nolvadex®) 269
temsirolimus (Torisel®) 269
temozolomide (Temodar®) 269
thalliumomide (Thalomid®) 270
vinblastine (Velban®) 270
vincristine (Oncovin®) 270
zoledronic acid (Zometa®) 270

drug:supplement interactions of interest to cancer survivors 70

DTIC-dome® (dacarbazine) 109
dumping syndrome 183,190,257-260
dysphagia 88,117,236
dysthesia 110,268

E
early dumping 257,260

Eastern Cooperative Oncology Group (ECOG) status 251
extracorporeal photopheresis (ECP) 160
Ellence® (epirubicin) 111,174,182,189
Eloxatin® (oxaliplatin) 110,182,189,223,268
endocrine and exocrine effects of neuroendocrine tumors 139
energetics, exercise and cancer - chapter 41-46
Index: Oncology Nutrition for Clinical Practice

- calorie restriction and cancer prevention 43
- cancers associated with lifestyle habits 41
- exercise and cancer survivors 43
- exercise during cancer treatment 44
- obesity and cancer risk 41
- post-treatment exercise and cancer outcomes 44
- promoting physical activity 44
- recommendations for physical activity for cancer survivors 43
- weight and cancer outcomes 42
- weight during treatment and post-treatment 43

energy balance and cancer 15-16, 41-42, 44, 54, 90, 93

energy density (definition) 16

energy needs
- adults 35-38
- pediatrics 147-149

teral nutrition
- administration 125
- advanced cancer 245
- blenderized tube feeding recipe 132
- complications 125-127
- contraindications 124
- esophageal cancer 184-184
- feeding routes and considerations 124
- formulations and modular nutrients 124-125
- gastric cancer 190
- gastric residual volumes 126
- head and neck cancer 203-207
- hematopoietic cell transplantation 158-159
- indications/benefits in the oncology setting 123
- medication interactions 126
- pediatric patients 153

Entocort EC®, Uceris® for oral; others for inhaled form (budesonide) 160

epigenetics and cancer 82

epirubicin (Ellence®) 111, 174, 182, 189

Erbitux® (cetuximab) 113, 182, 189, 202, 267

erlotinib (Tarceva®) 223, 267
Index: Oncology Nutrition for Clinical Practice

esophageal cancer
- chapter (medical nutrition therapy for esophageal cancer) 181-186
- anatomical changes in esophagectomy 183
- dumping syndrome / anti-dumping diet 183
- enteral nutrition 184-185
- malnutrition 184
- nutrition impact symptoms of common treatment agents 182
- nutrition needs 184
- nutrition risk screening and assessment 184
- risk factors 181-182
- surgery 183

esophagitis (symptom management) 119

essiac/flor-essence 63

etoposide (Vepesid®, VP-16) 112,214

Eulexin® (flutamide) 103

everolimus (afinitor®) 268

evidence-based cancer care 97

Evista® (raloxifene) 103

exemestane (Aromasin®) 103,175,268

Exjade® (deferasirox) 267

extracorporeal photopheresis (ECP) 160

F
factors affecting response to cancer treatment 98

Fareston® (toremifene citrate) 103

Faslodex® (fulvestrant) 175

fasting 64

fatigue (symptom management) 89,118
### Index: Oncology Nutrition for Clinical Practice

- **fats**
  - fat (dietary) and cancer survivorship  
  - fatty acids and breast cancer
  - oleic acid
  - omega-3 fatty acids  
  - omega-9 fats

- **Femara® (letrozole)**

- **fiber**

- **flaxseed**

- **Flor-Essence (Essiac)**

- **Fludara® (fludarabine)**

- **fludarabine (Fludara®)**

- **fluorouracil (5-FU, Adrucil®)**

- **flutamide (Eulexin®)**

- **folic acid**

- **fructo-oligosaccharides**

- **fruits and vegetables**

- **fulvestrant (Faslodex®)**

- **functional foods**
  - definition
  - in the health care continuum
  - functional food sources of cancer-fighting compounds

- **G**

- **gabapentin (Neurontin®)**

- **gallbladder cancer**

- **garlic**

- **gastric cancer**
Index: Oncology Nutrition for Clinical Practice

gastrointestinal tract cancers 187-199
(also see nutrition management for cancers of the gastrointestinal tract)

gefitinib (Iressa®) 268

gemcitabine (Gemzar®) 110,174,189,202,214,223
Gemzar® (gemcitabine) 110,174,189,202,214,223

genetic variations and cancer risk 81

genistein 67

Gerson Diet 64

ginger 76

gingko biloba 76

Gleevec® (imatinib mesylate) 268

Gleostine®, CeeNU®, CCNSB® (lomustine systemic) 167

glutamine 76,211

Gonzalez Regimen 64

goserelin (Zoladex®) 103,175

graft versus host disease 160-161

grapefruit/grapefruit juice 267-270

graphics 165
- brain 165
- colon 139
- colorectal surgery resections 192
- esophagectomy 183
- head and neck 201
- gallbladder 195
- liver 139
- lung 209
- ovaries 213
- parts of small intestines 138
Index: Oncology Nutrition for Clinical Practice

- prostate gland 229
- sites of nutrient absorption 187
- stomach 137
- thyroid gland 235

green tea 21,57,178,232,267

H
hand and foot syndrome 101,110-111,267-268

head and neck cancer (HNC)
- chapter (medical nutrition therapy for HNC) 201-208
- medical treatment 202-203
- nutrition challenges/goals 203
- nutrition implications of chemotherapy agents 202
- nutritional phases of chemo-radiation treatment 204-207
- oral toxicity scale (WHO) 203
- risk factors 201

hematopoietic stem cell transplant (adults)
- chapter (medical nutrition therapy for hematopoietic cell transplantation) 157-163
- diet for GI symptoms of graft versus host disease (GVHD) 161
- diet for immunosuppressed patients 159
- long-term complications/management 160-162
- medical treatment for GVHD 160
- nutrient considerations 159-160
- nutrient needs 158
- nutrition support 158-159
- nutrition assessment 157

hematopoietic stem cell transplant (pediatric) 153-154

hepatocellular cancer 194-195

Herceptin® (trastuzumab) 113,175,182,189

Hexalen® (altretamine) 214

hormonal agents used in cancer treatment 103

hormone-receptive breast cancers 172

hospice care
## Index: Oncology Nutrition for Clinical Practice

**- chapter (nutrition management of oncology patients in palliative and hospice settings)** | 241-247

**Hycamtin® (topotecan)** | 182,214

| **I** |  
|---|---|
| ibritumomab tiuxetan (Zevalin®) | 113 |
| Idamycin® (idarubicin) | 111 |
| idarubicin (Idamycin®) | 111 |
| Ifex® (Ifosfamide) | 109,202,214 |
| Ifosfamide (Ifex®) | 109,202,214 |
| Ileostomy (diet and nutrition guidelines) | 261 |
| imatinib mesylate (Gleevec®) | 268 |
| Imuran®, Azasan® (azathioprine) | 160 |
| inherited cancer syndromes | 81-82 |
| Inlyta® (axitinib) | 267 |

**integrated oncology: the role of nutrition**
- chapter | 53-60
- anti-cancer nutrition | 54-55
- components of an integrative oncology program | 53-54
- dietary supplements | 55-56
- nutraceuticals | 56-57
- pancreatic cancer | 223
- pediatric patients | 152

**integrated use of diets in cancer treatment/survival** | 62-65

**integrated use of functional foods in cancer treatment/survival** | 66-68

**interferon-α (Roferon-A®, Intron®)** | 102
**interleukin-2 or IL-2 (aldesleukin®)** | 102
**Intron®, Roferon-A® (interferon-α)** | 102
Index: Oncology Nutrition for Clinical Practice

inulin 67

iodine
- low iodine diet 236-239

Iressa® (gefitinib) 268

irinotecan (Camptosar®) 167,182,189,214,223

iron overload 161-162

ixabepilone (Ixempra®) 174

Ixempra® (ixabepilone) 174

K
Kadcyla® (ado-trastuzumab emtansine) 113

Karnofsky Performance Status Scale 251

Keppra® (levetiracetam) 167

ketogenic diet 168,266

L
lapatinib (Tykerb®) 175,268

late dumping syndrome 257,260

letrozole (Femara®) 103,175

Leukeran® (chlorambucil) 109,267

leukemia (nutrition complications and management) 89

leuprolide (Lupron®) 103,175

levetiracetam (Keppra®) 167

lifetime risk of developing cancer (cancer statistics) 9

Livingston-Wheeler Diet 65
Index: Oncology Nutrition for Clinical Practice

lomustine systemic (Gleostine®, CeeNU®, CCNSB®) 167

low-iodine diet 236-239

lung cancer
- chapter (medical nutrition therapy for lung cancer) 209-212
- chemotherapy induced peripheral neuropathy and glutamine 211
- medical treatments 210
- nutrition intervention in advanced stages 211
- nutrition needs 211
- nutrition risk screening & assessment 210
- risk factors 209

Lupron® (leuprolide) 103,175

lutein 67

lycopene 67,232

lymphedema 175

M
macrobiotic diet 65

macronutrient needs for adults 33-35

malabsorption 88-89,118

malnutrition
- and cancer 25
- clinical characteristics 29-30
- definition 28
- in esophageal cancer 184
- in palliative/hospice settings 241-243
- in pediatric oncology 143-147
- malnutrition screening tool (MST) 26
- malnutrition screening tool for cancer patients (MSTC) 26
- malnutrition universal screening tool (MUST) 26

Matulane® (procarbazine hydrochloride) 167,269

MCT oil 265
Index: Oncology Nutrition for Clinical Practice

measuring outcomes of oncology nutrition programs 51

mechlorethamine (nitrogen mustard, Mustagen®) 109

medical nutrition therapy/nutrition intervention for
- breast cancer 176
- colorectal cancer 193
- dumping syndrome 183,260-261
- gastric cancer 190
- head/neck cancer 204,206
- neuroendocrine tumors 139
- ovarian cancer 216-217
- pancreatic cancer 221
- prostate cancer 231
- surgical issues (e.g., gastric transit abnormalities) 140

medicinal mushrooms 57

Megace® (megestrol acetate) 103

megestrol acetate (Megace®) 103

melatonin 70

melphalan (Alkeran®) 110,214,268

mercaptopurine (6-MP or Purinethol®) 110,268

metabolic changes in cancer 33

metastatic bone pain 107

Metastron® (strontium 89) 107

methotrexate (MTX) 11,111,160,174,182,202,268

micronutrients (also see dietary supplements) 35,56,69-72

mitomycin (Mutamycin®) 111,182,189,223

monoamine oxidase (MAO) 115,269

monoclonal antibodies 113,160

MTX (methotrexate) 11,111,160,174,182,202,268
Index: Oncology Nutrition for Clinical Practice

mucositis 119

Mutamycin® (mitomycin) 111, 182, 189, 223

mycophenolate mofetil (Cellcept®) 160

Mylaran® (busulfan) 109, 267

N National Comprehensive Cancer Network (NCCN) Cancer Survivorship Guidelines 97, 249

nausea/vomiting 89, 119, 260

Navelbine® (vinorelbine) 112, 174, 182, 214

neuroendocrine tumors 139

Neurontin® (gabapentin) 167

Nexavar® (sorafenib) 189, 269

nilotinib (Tasigna®) 268

Nipent® (pentostatin) 160

Nolvadex® (tamoxifen) 103, 175, 269

non-Hodgkin’s lymphoma 88

nutraceuticals 56-57

nutrient absorption 187

nutrient requirements (including DRIs and RDAs)
- calorie and protein requirements for pediatric HSCT patients 154
- daily calcium requirements for children (RDAs) 151
- daily vitamin D requirements (RDAs) 150
- DRIs for estimating energy requirements for children 148-149
- DRIs for protein intake for children 150
- DRIs, RDAs, AIs for macronutrients, fiber, and water for adults 34
- Holliday Segar method for estimating fluid maintenance needs 150
- protein requirements in health and disease (adults) 34
# Index: Oncology Nutrition for Clinical Practice

nutrigenomics and cancer
- chapter 79-85
- carcinogenesis 79-80
- diet and nutrition recommendations for cancer prevention & survivorship 82
- epigenetics and cancer 82
- future research 83
- glossary of terms 80
- genetic variation and cancer risk 81
- inherited cancer syndromes 81-82
- nutritional genomics (definition) 79

nutrition and cancer prevention
- chapter 15-24
- AICR/WCRF personal recommendations 17
- alcoholic drinks 18-19
- anti-cancer nutrition 54-55
- body fatness/weight 15-16
- breastfeeding 19-20
- dietary supplements 19
- energy density 16
- flaxseed 21
- green tea 21
- omega-3 fatty acids 20
- physical activity 16
- plant-based diet 16-18
- red and processed meats 18
- salt/sodium 19
- soy 20-21

nutrition and cancer survivorship
- chapter 87-96
- biology of weight change in cancer survivors 91
- dietary guidance; a role for specific foods 92-93
- dietary interventions for bone and muscle health 93
- dietary intervention studies in cancer survivors 91-92
- dietary supplementation for survivors 93-94
- long-term nutrition related complications of common cancers 88-89
- obesity in the post-treatment setting 90-91
- resources for cancer survivors 90
- select randomized clinical trials addressing nutrition and cancer survivorship 92
- the cancer survivor 87

nutrition assessment
- for patients with brain tumors 166
Index: Oncology Nutrition for Clinical Practice

- definition 27
- for hematopoietic cell transplantation 157-158
- for patients with prostate cancer 233
- for pediatric patients 151-152
- for surgical patients 135

nutrition diagnoses for long term nutrition related complications of cancer 88-89

nutrition impact symptoms
- and quality of life 241-242
- for agents used to treat brain tumors 167
- for agents used to treat breast cancer 173
- for chemotherapy agents used to treat head and neck cancer 202
- for chemotherapy agents used to treat ovarian cancer 214
- for treatments of GI cancers 189
- for treatments of pancreatic cancer 223
- prevalence in cancer patients 242
- symptom management for nutrition impact symptoms 115-121

nutrition issues and outcomes across the cancer continuum 13

nutrition management for cancers of the GI tract:
- chapter 187-199
- introduction to GI cancers 187
- nutrient needs for cancers of the GI tract 187-188
- nutrition absorption in the GI tract 187
- nutrition related effects of GI cancer treatments 189

anal cancer
- medical treatments/nutrition implications 197
- overview 196
- risk factors 197

colorectal cancer (CRC)
- diet and lifestyle recommendations for CRC survivors 193
- medical nutrition therapy / nutrition management 192-193
- medical treatments 191-192
- overview 191
- risk factors 191

gallbladder cancer
- nutrition management 196
- overview 195
- risk factors 195
- treatment options 196
Index: Oncology Nutrition for Clinical Practice

gastric cancer
- medical nutrition therapy 190
- overview 188
- risk factors 188-189
- treatments 189-190

hepatocellular cancer
- overview 194
- risk factors 194
- signs and symptoms 195
- treatments 194-195

nutrition management of oncology patients in palliative and hospice settings 214-247
- chapter 241-247
- artificial nutrition and hydration 243-244
- definitions 241
- nutrition impact symptoms and quality of life 241-242
- nutrition screening and assessment 242-243
- nutrition support in advanced cancer 245

nutrition management of the surgical oncology patient
- chapter 135-142
- colorectal surgery 138,192
- diet after intestinal surgery 253-255
- esophageal surgery 137,183
- head and neck surgery 136
- long-term feeding/nutrition issues 140
- pancreatic surgery 139
- peritoneal surgery 136
- post-operative nutrition issues 136
- pre-operative nutrition issues and education 135
- small bowel surgery 138
- stomach surgery 137-138

nutrition-related (and long term) complications of common cancers by cancer site 88-89

nutrition risk screening and assessment of the oncology patient
- chapter 25-32
- effects of malnutrition on the oncology patient 25
- evidence based nutrition assessment 26-28
- malnutrition (definition/characteristics) 28-31
- nutrition screening 25-26
- screening tools validated for oncology patients 26
Index: Oncology Nutrition for Clinical Practice

- screening & assessment in hospice/palliative care 242-243
- screening & assessment in lung cancer 210
- screening & assessment in ovarian cancer 215
- screening & assessment in pediatric cancers 151-152
- screening & assessment in prostate cancer 233

nutrition support in the oncology setting
- chapter 123-133
- administration of enteral feeding 125
- blenderized tube feeding recipes 132-133
- feeding routes and considerations (enteral nutrition) 124
- formulations and modular nutrients (enteral nutrition) 125
- gastrointestinal complications (enteral nutrition) 127
- lab and tolerance monitoring for parenteral nutrition 130
- macronutrients in parenteral nutrition solutions 128
- metabolic complications & potential corrections during EN therapy 126
- monitoring gastric residual volumes 126
- nutrition support in palliative care and end of life 131,243-244
- nutrition support for advanced cancer patients 245
- standard adult parenteral trace element additives 129
- standard adult parenteral vitamin additives 129
- standard parenteral electrolyte requirements 129

nutritional effects of cancer medications/treatments: chemotherapy, biotherapy, hormone therapy and radiation therapy
(® = brand name)
- chapter 97-113
- ado-trastuzumab emtansine (Kadcyla®) 113
- anastrozole (Arimidex®) 103
- azacitidine (Vidaza®) 110
- bendamustine (Treanda®) 109
- bevacizumab (Avastin®) 101
- bicalutamide (Casodex®) 103
- bleomycin (Blenoxane®) 111
- busulfan (Myleran®) 109
- capecitabine (Xeloda®) 110
- carboplatin (Paraplatin®) 109
- carboplatin (Platinol®, CDDP) 109
- carmustine (BCNU®) 109
- cetuximab (Erbitux®) 113
- chlorambucil (Leukeran®) 109
- cisplatin (Platinol®, CDDP) 109
- cyclophosphamide (Cytoxan®, CTX) 109
- cytarabine, ARA-C (Cytosar-U®) 110
- dacarbazine (DTIC-dome®) 109
- dactinomycin (Cosmegen®) 111
Index: Oncology Nutrition for Clinical Practice

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>daunorubicin (Daunomycin®)</td>
<td>111</td>
</tr>
<tr>
<td>denosumab (Xgeva®, Prolia®)</td>
<td>113</td>
</tr>
<tr>
<td>docetaxel (Taxotere®)</td>
<td>112</td>
</tr>
<tr>
<td>doxorubicin (Adriamycin®)</td>
<td>111</td>
</tr>
<tr>
<td>doxorubicin liposomal (Doxil®)</td>
<td>111</td>
</tr>
<tr>
<td>epirubicin (Ellence®)</td>
<td>111</td>
</tr>
<tr>
<td>etoposide (Vepesid®, VP-16)</td>
<td>112</td>
</tr>
<tr>
<td>exemestane (Aromasin®)</td>
<td>103</td>
</tr>
<tr>
<td>fludarabine (Fludara®)</td>
<td>110</td>
</tr>
<tr>
<td>fluorouracil (5-FU)</td>
<td>110</td>
</tr>
<tr>
<td>flutamide (Eulexin®)</td>
<td>103</td>
</tr>
<tr>
<td>gemcitabine (gemzar®)</td>
<td>110</td>
</tr>
<tr>
<td>goserelin (Zoladex®)</td>
<td>103</td>
</tr>
<tr>
<td>ibritumomab tiuxetan (Zevalin®)</td>
<td>113</td>
</tr>
<tr>
<td>idarubicin (Idamycin®)</td>
<td>111</td>
</tr>
<tr>
<td>ifosfamide (Ifex®)</td>
<td>109</td>
</tr>
<tr>
<td>interferon-a (Roferon® or Intron A®)</td>
<td>102</td>
</tr>
<tr>
<td>interleukin-2 or IL-2 (Aldesleukin®)</td>
<td>102</td>
</tr>
<tr>
<td>letrozole (Femara®)</td>
<td>103</td>
</tr>
<tr>
<td>leuprolide acetate (Lupron®)</td>
<td>103</td>
</tr>
<tr>
<td>mechlorethamine (nitrogen mustard)</td>
<td>109</td>
</tr>
<tr>
<td>megestrol acetate (Megace®)</td>
<td>103</td>
</tr>
<tr>
<td>melphalan (Alkeran®)</td>
<td>110</td>
</tr>
<tr>
<td>megestrol acetate (Megace®)</td>
<td>103</td>
</tr>
<tr>
<td>mercaptopurine (6-MP)</td>
<td>110</td>
</tr>
<tr>
<td>methotrexate (MTX)</td>
<td>111</td>
</tr>
<tr>
<td>mitomycin-C (Mutamycin®)</td>
<td>111</td>
</tr>
<tr>
<td>oxaliplatin (Eloxatin®)</td>
<td>110</td>
</tr>
<tr>
<td>paclitaxel (Taxol®)</td>
<td>112</td>
</tr>
<tr>
<td>paclitaxel protein-bound (Abraxane®)</td>
<td>112</td>
</tr>
<tr>
<td>panitumumab (Vectibix®)</td>
<td>113</td>
</tr>
<tr>
<td>pertuzumab (Perjeta®)</td>
<td>113</td>
</tr>
<tr>
<td>pemetrexed (Alimta®)</td>
<td>111</td>
</tr>
<tr>
<td>radium 223 (Xofigo®)</td>
<td>107</td>
</tr>
<tr>
<td>raloxifene (Evista®)</td>
<td>103</td>
</tr>
<tr>
<td>rituximab (Rituxan®)</td>
<td>113</td>
</tr>
<tr>
<td>samarium 153 (Quadramet®)</td>
<td>107</td>
</tr>
<tr>
<td>strontium 89 (Metastron®)</td>
<td>107</td>
</tr>
<tr>
<td>tamoxifen (Novaldex®)</td>
<td>103</td>
</tr>
<tr>
<td>toremifene citrate (Fareston®)</td>
<td>103</td>
</tr>
<tr>
<td>temozolomide (Temodar®)</td>
<td>110</td>
</tr>
<tr>
<td>teniposide (Vumon®, VM-26)</td>
<td>112</td>
</tr>
<tr>
<td>thioguanine (6-TG)</td>
<td>111</td>
</tr>
<tr>
<td>thiotepa (Thioplex®)</td>
<td>110</td>
</tr>
<tr>
<td>trastuzumab (Herceptin®)</td>
<td>113</td>
</tr>
</tbody>
</table>
Index: Oncology Nutrition for Clinical Practice

vinblastine (Velban®) 112
vincristine (Oncovin®) 112
vinorelbine (Navelbine®) 112

nutritional effects of cancer treatments
- brain tumors 167
- breast cancer 173
- esophageal cancer 182
- GI cancer 189
- head & neck cancer 202
- ovarian cancer 214
- pancreatic and bile duct cancer 223

nutritional management of the pediatric oncology patient
- chapter 143-156
- cachexia 144
- integrative oncology for pediatrics 152
- malnutrition 143-147
- nutrition needs 145,147-151
- pediatric hematopoietic stem cell transplant 153-154
- prevalence of common childhood cancers 143
- specialized nutrition support 153
- subjective global nutritional assessment for children 146-147

nutritional needs of the adult oncology patient
- chapter 33-39
- adjusted body weight 38
- breast cancer survivors 176
- childhood cancers 145,148-151
- conditions affecting vitamin/mineral levels 35
- conditions influencing indirect calorimetry 36
- dietary reference intakes 33
- esophageal cancer 184
- GI cancers 187-188
- hematopoietic cell transplantation (adults) 158
- hematopoietic cell transplantation (pediatrics) 154
- lung cancer 211
- macronutrient needs 33-38
- metabolic changes in cancer 33
- micronutrient needs 35
- ovarian cancer 215
- predictive equations for energy needs 37
- refeeding syndrome 38
Index: Oncology Nutrition for Clinical Practice

O
obesity/energy balance and cancer 15-16, 42,44,54,90,93

oleic acid 70

omega-3 fatty acids
- omega-3 fats and breast cancer 177
- omega-3 fats and cancer prevention 20
- omega-3 fats and nutrition/prostate cancer risk 230
- omega-3 fats and nutrition recommendations for prostate cancer survivors 232
- omega-3 fat as a functional food 72
- omega-3 fats as a nutraceutical 56
- omega-3 fats in table of select drugs & supplement interactions 70

omega-9 fatty acids 230,232

oncology nutrition program in a cancer center 47
- components 47
- definition 47
- guidelines for nutrition care 48
- organization 48-49

Oncovin® (vincristine) 112,167,270

oral candidiasis 117

oral toxicity scale (WHO) 203

ovarian cancer
- chapter 213-218
- disease staging 214
- medical nutrition therapy 216-217
- medical treatments 214
- nutrition impact symptoms of select therapies 214
- nutrition risk screening and assessment 215
- risk factors 213
- survivorship 216

oxaliplatin (Eloxatin®) 110,182,189,223,268

oxcarbazepine (Trileptal®) 167

P
paclitaxel (Taxol®) 112,174,182,189,202,214,223
paclitaxel protein-bound (Abraxane®) 112

palliative and hospice care
  - chapter 241-247
  - artificial nutrition and hydration 243-244
  - definitions 241
  - nutrition impact symptoms and quality of life 241-242
  - nutrition screening and assessment 242-243
  - nutrition support in advanced cancer 245

pancreatic and bile duct cancer
  - chapter 219-227
  - diabetes 224
  - gastric outlet/duodenal/small bowel obstruction 225-226
  - medical/surgical treatments 221-222
  - nutrition impact symptoms 221,223
  - nutrition needs 220
  - nutrition risk factors 220
  - pancreatic enzyme replacement products 225
  - pancreatic exocrine insufficiency 224
  - signs/symptoms of pancreatic exocrine insufficiency 224

pancreatic exocrine insufficiency and enzyme replacement 224-225

panitumumab (Vectibix®) 113,189,269

Paraplatin® (carboplatin) 109,182,189,202

parenteral nutrition
  - access 127
  - complications 130
  - components 128-129
  - hematopoietic cell transplantation 159
  - home setting 130
  - indications 127
  - initiation 129
  - monitoring 129-130
  - palliative setting 131
  - pediatrics 153
  - trace element and vitamin additives 129
  - transition to oral nutrition 130
Index: Oncology Nutrition for Clinical Practice

pediatric oncology 143-156
(also see nutritional management of the pediatric oncology patient)

pemetrexed (Alimta®) 214,269
pentostatin (Nipent®) 160
performance status 251
Perjeta® (pertuzumab) 113,175
pertuzumab (Perjeta®) 113,175
phenytoin (Dilantin®) 167

physical activity 16-17
- and cancer prevention 16-17
- and cancer survivors 43
- during cancer treatment 44
- integrative oncology 54

plant based diet 16-17,54,61,1230

plants and pharmaceuticals 68

Platinol® (cisplatin) 109,182,189,202,214,223,267

procarbazine hydrochloride (Matulane®) 167,269

Prograf®, Astagraf XL® (tacrolimus) 160

Prolia®, Xgeva® (denosumab) 113

prostate cancer 229-234
- chapter 229-234
- medical nutrition therapy 231
- medical treatment 230
- nutrition recommendations for survivors 232
- nutrition screening and assessment 233
- risk factors 229-231
- stages of prostate cancer 229

protein targeted therapies 100-101

Provenge® (sipuleucel-T) 269
Index: Oncology Nutrition for Clinical Practice

PSA screening and prostate cancer  229
psoralen + ultraviolet light (multiple brand names)  160
public health guidelines for cancer prevention/survivorship  249
Purinethol® (mercaptopurine or 6-MP)  110,268

Q
Quadramet® (samarium 153)  107
quercetin  69-70
Qvar®, Beconase AQ® (beclomethasone dipropionate)  160

R
radiation therapy  102-104
- external beam radiation therapy  102-104
- possible acute effects of site-specific radiation therapy  105
- possible late side effects of radiation therapy  105
- possible side effects of total body radiation therapy  106
- radioimmunotherapy agents  104
radium 223 (Xofigo®)  107
raloxifene (Evista®)  103
randomized controlled trials (RCTs) on antioxidant supplementation and cancer risk  71
randomized controlled trials (RCTs) on vitamin D/calcium supplements and colon, breast, and prostate cancer  71
Rapamune® (sirolimus)  160
raw food diet plan  65
red and processed meats  18,232
refeeding syndrome  38
regorafenib (Stivarga®)  189,269
## Index: Oncology Nutrition for Clinical Practice

### resources
- for cancer survivors 90
- for dietary supplements 72

### risk factors for cancer
- anal cancer 197
- breast cancer 171
- colorectal cancer 191
- esophageal cancer 181-182
- gallbladder cancer 195
- gastric cancer 188
- head and neck cancer 201
- hepatocellular cancer 194
- lung cancer 209
- ovarian cancer 213
- prostate cancer 229-230
- thyroid cancer 235-236

Rituxan® (rituximab) 113

rituximab (Rituxan®) 113

Roferon-A®, Intron® (interferon-a) 102

**S**

salt/sodium 19,249

samarium 153 (Quadramet®) 107

Sandimmune® (cyclosporine) 160

selenium 231

side effects and nutritional implications of cytokines 102

side effects of brachytherapy (possible) 107

side effects of chemotherapy 109-112
(specific drugs also listed under each drug’s name) (additional information listed under symptom management)

side effects of monoclonal antibodies 113
Index: Oncology Nutrition for Clinical Practice

side effects of radiation therapy (late effects) 105
side effects of radiopharmaceuticals for metastatic bone pain 107
side effects of site-specific radiation therapy (acute effects) 105
side effects of total body radiation 106
silymarin 76
sipuleucel-T (Provenge®) 269
sirolimus (Rapamune®) 160
sorafenib (Nexavar®) 189,269
soyfood 20,177,230,232
Sprycel® (dasatinib) 267
St. John's Wort 76, 267-270
standards of practice (SOP) in oncology nutrition care 49
standards of professional performance in oncology nutrition care 49
Stivarga® (regorafenib) 189,269
streptozocin (Zanosar®) 269
stress management 58
strontium 89 (Metastron®) 107
Sutent® (sunitinib) 269
surgical oncology 135-142
(also see nutrition management of the surgical oncology patient)
sunitinib (Sutent®) 269
symptom management of cancer therapies 115-121
- chapter 115
- anorexia/poor appetite/early satiety 115
- constipation 116
Index: Oncology Nutrition for Clinical Practice

- diarrhea  116
- dysphagia  117
- fatigue  118
- malabsorption  118
- mucositis/esophagitis  119
- nausea/vomiting  119
- oral candidiasis  117
- taste and smell changes  120
- xerostomia/thick saliva  120

T tacrolimus (Prograf®, Astagraf XL®)  160

tamoxifen (Nolvadex®)  103,175,269
Tarceva® (erlotinib)  223,267
Targetretin® (bexarotene)  267
Tasigna® (nilotinib)  268
taste and smell changes  120

Taxol® (paclitaxel)  112,174,182,189,202,214,223
Taxotere® (docetaxel)  112,173,182,189,202,223

Tegretol® (carbamazepine)  167
Temodar® (temozolomide)  110,167,269
temozolomide (Temodar®)  110,167,269
temsirolimus (Torisel®)  269
teniposide (Vumon®, VM-26)  112

thalidomide (Thalomid®)  160,270
Thalomid® (thalidomide)  160,270
theanine  76

Thioplex® (thiotepa)  110
Index: Oncology Nutrition for Clinical Practice

thioguanine (6-TG) 111
thiotepa (Thioplex®) 110
Thymoglobulin® (anti-thymocyte globulin) 160
Topamax® (topiramate) 167
topiramate (Topamax®) 167
topotecan (Hycamtin®) 182,214
toremifene citrate (Fareston®) 103
Torisel® (temsirolimus) 269
trastuzumab (Herceptin®) 113,175,182,189
Treanda® (bendamustine) 109
Trileptal® (oxcarbazepine) 167
tumor, lymph nodes, and metastasis (TNM) cancer staging system 9-10
thyroid cancer
- chapter 235-240
- low iodine diet 236-239
- medical treatments 236
- risk factors 235-236
- types of thyroid cancer 236
tube feedings
- blended tube feeding recipe 132-133
- see enteral nutrition 123-127
Tykerb® (lapatinib) 175,268

U
Üceris®, Entocort EC® for oral; others for inhaled form (budesonide) 160
uterine cancer (uterine corpus) 88
ursodeoxycholic acid (over 20 brand names are available) 160
Index: Oncology Nutrition for Clinical Practice

V
Vectibix® (panitumumab) 113,189,269
vegetables/fruit 93,249,258,262
Velban® (vinblastine) 112,270
Velcade® (bortezomib) 267
Vepesid®, VP-16 (etoposide) 112,214
vinblastine (Velban®) 112,270
vincristine (Oncovin®) 112,167,270
vinorelbine (Navelbine®) 112,174,182,214
vitamin/mineral malabsorption 190
vitamin/mineral supplementation 69
vitamin A 267
vitamin B6 267-268
vitamin B12 269
vitamin C 71
vitamin D 56,70-72,230-232
vitamin E 71,231-232
VP-16, Vepesid® (etoposide) 112,214
Vumon® (teniposide, VM-26) 112

W
weight
- and cancer outcomes 42
- and prostate cancer 231
- during treatment and post-treatment 43
Index: Oncology Nutrition for Clinical Practice

- weight change in cancer survivors 43,88-89,91
World Health Organization Cancer Prevention Guidelines 249

X
Xeloda® (capecitabine) 110,173,182,189,214,223,267
xerostomia/thick saliva 120
Xgeva®, Prolia® (denosumab) 113
Xofigo® (radium 223) 107

Z
Zaltrap® (ziv-aflibercept) 189
Zanosar® (streptozocin) 269
Zevalin® (ibritumomab tiuxetan) 113
zinc 71
ziv-aflibercept (Zaltrap®) 189
Zoladex® (goserelin) 103,175
zoledronic acid (Zometa®) 270
Zometa® (zoledronic acid) 270